2. Search Result
Search Result
Results for "

Crohns disease

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

4

Peptides

16

Inhibitory Antibodies

5

Natural
Products

1

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P990007
    Tulisokibart

    PRA023; PRA-023

    		 TNF Receptor Inflammation/Immunology
    Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) .
    Tulisokibart
  • HY-P9953
    Certolizumab pegol

    Certolizumab; CDP870

    		 TNF Receptor Inflammation/Immunology Cancer
    Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
    Certolizumab pegol
  • HY-P990006
    Duvakitug

    		TNF Receptor Inflammation/Immunology
    Duvakitug is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
    Duvakitug
  • HY-P99292
    Fontolizumab

    HuZAF; Anti-Human IFNG Recombinant Antibody

    		 IFNAR Inflammation/Immunology
    Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
    Fontolizumab
  • HY-106539
    Colesevelam hydrochloride

    		Others Metabolic Disease Cancer
    Colesevelam (hydrochloride) is a bile acid sequestrant that bind bile acids in the gut. Colesevelam (hydrochloride) inhibits bile acid reabsorption, leading to increased bile acid synthesis and reduced cholesterol levels in patients with cholestatic pruritus and Crohn’s disease.
    Colesevelam hydrochloride
  • HY-P2221B
    Glepaglutide acetate

    ZP1848 acetate

    		 GCGR Inflammation/Immunology
    Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .
    Glepaglutide acetate
  • HY-P99821
    Ravagalimab

    ABBV-323

    		 TNF Receptor Inflammation/Immunology
    Ravagalimab (ABBV-323) is a CD40 antagonist (EC50: 3.7 nM). Ravagalimab can be used for research of Crohn's disease .
    Ravagalimab
  • HY-P9911
    Vedolizumab
    1 Publications Verification

    Anti-Human lymphocyte α4β7 integrin, Humanized Antibody

    		 Integrin Inflammation/Immunology Cancer
    Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
    Vedolizumab
  • HY-115497
    BRD5529

    		E1/E2/E3 Enzyme Infection Inflammation/Immunology
    BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) .
    BRD5529
  • HY-P2221
    Glepaglutide

    ZP1848

    		 GCGR Inflammation/Immunology
    Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .
    Glepaglutide
  • HY-B1046S
    Clofazimine-d7

    		Bacterial Antibiotic Inflammation/Immunology
    Clofazimine-d7 is deuterium labeled Clofazimine. Clofazimine is an iminophenazine dye, has a marked anti-inflammatory effect, has been used in combination with other antimycobacterial agents to treat AIDS and Crohn's disease.
    Clofazimine-d7
  • HY-P99485
    Brazikumab

    AMG 139; MEDI2070

    		 Interleukin Related Inflammation/Immunology
    Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
    Brazikumab
  • HY-P99332
    Visilizumab

    Anti-Human CD3E Recombinant Antibody; HuM291

    		 Apoptosis Inflammation/Immunology Cancer
    Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
    Visilizumab
  • HY-141521
    Amelenodor

    NX-13

    		 NOD-like Receptor (NLR) Inflammation/Immunology
    NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn's disease and ulcerative colitis .
    Amelenodor
  • HY-P9911A
    Vedolizumab (anti-α4β7-integrin)

    		Integrin Inflammation/Immunology
    Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
    Vedolizumab (anti-α4β7-integrin)
  • HY-145721A
    Mongersen sodium

    GED-0301 sodium

    		 TGF-beta/Smad Inflammation/Immunology
    Mongersen sodium is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen sodium restores TGF-β1 activity leading to inhibition of inflammatory signals. Mongersen sodium can attenuate Crohn's disease-like experimental colitis in mice .
    Mongersen sodium
  • HY-145721
    Mongersen

    GED-0301

    		 TGF-beta/Smad Inflammation/Immunology
    Mongersen (GED-0301) is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen restores TGF-β1 activity leading to inhibition of inflammatory signals. Mongersen can attenuate Crohn's disease-like experimental colitis in mice .
    Mongersen
  • HY-P99190
    Eldelumab

    BMS-936557; MDX-1100

    		 CXCR Inflammation/Immunology
    Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
    Eldelumab
  • HY-P99737
    Mirikizumab

    LY­3074828

    		 Interleukin Related Inflammation/Immunology
    Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
    Mirikizumab
  • HY-108831
    Natalizumab
    2 Publications Verification

    		 Integrin Inflammation/Immunology Cancer
    Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
    Natalizumab
  • HY-P99111
    Golimumab

    CNTO-148

    		 TNF Receptor Apoptosis Interleukin Related Caspase Inflammation/Immunology Cancer
    Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
    Golimumab
  • HY-N2199
    Sotetsuflavone

    		Apoptosis Autophagy Cancer
    Sotetsuflavone is a flavonoid that can be isolated from Cycas revolute. Sotetsuflavone inhibits migration and invasion of A549 cells by reversing EMT, and induces cell apoptosis and autophagy. Sotetsuflavone inhibits HIF-1α, VEGF, angiostatin, MMP-9, and MMP-13 expression in A549 cells. Sotetsuflavone also protects mice against Crohn's disease (CD)-like colitis. Sotetsuflavone can be used for research of NSCLC .
    Sotetsuflavone
  • HY-108831A
    Natalizumab (Solution)
    2 Publications Verification

    		 Integrin Inflammation/Immunology
    Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
    Natalizumab (Solution)
  • HY-117803
    CP 461 free base

    OSI-461 free base

    		 Others Cancer
    CP 461 free base (OSI-461 free base) is a novel pro-apoptotic compound with the activity of inhibiting cyclic guanosine monophosphate phosphodiesterase. CP 461 free base exhibits growth inhibitory activity against a variety of human tumor cell lines in vitro. CP 461 free base selectively induces apoptosis in cancer cell lines but has no effect on normal cells. CP 461 free base can be used in the study of renal cell carcinoma, prostate cancer and Crohn's disease .
    CP 461 free base

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: